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Our lab developed 99mTc-NTP 15-5 radiotracer as targeting proteoglycans (PGs) for the scintigraphic imaging of joint. This paper
reports preclinical results of 99mTc-NTP 15-5 imaging of an orthotopic model of Swarm rat chondrosarcoma (SRC). 99mTc-NTP
15-5 imaging of SRC-bearing and sham-operated animals was performed and quantiﬁed at regular intervals after surgery and
compared to bone scintigraphy and tumoural volume. Tumours were characterized by histology and PG assay. SRC exhibited
a signiﬁcant 99mTc-NTP 15-5 uptake at very early stage after implant (with tumour/muscle ratio of 1.61 ± 0.14), whereas no
measurable tumour was evidenced. As tumour grew, mean tumour/muscle ratio was increased by 2.4, between the early and late
stage of pathology. Bone scintigraphy failed to image chondrosarcoma, even at the later stage of study. 99mTc-NTP 15-5 imaging
provided a suitable set of quantitative criteria for the in vivo characterization of chondrosarcoma behaviour in bone environment,
useful for achieving a greater understanding of the pathology.
1.Introduction
Our laboratory has developed the 99mTc-N-[triethylammo-
nium]-3-propyl-[15]ane-N5 (99mTc-NTP 15-5) radiotracer
able to link proteoglycans (PGs) of cartilage, which was
demonstrated to allow scintigraphic imaging of joint [1–
6]. PG appear also as key partners in bone cell biology,
and might represent interesting targets for the assessment
of malignant pathological processes [7]. Chondrosarcoma
represent 25% of all bone sarcoma and are characterized by
the formation of a cartilage like extracellular matrix [8–10].
To the orthopedic oncologists, it is essential to identify the
lesions that are thought to constitute the “cartilage tumour
group”, through the presence of identiﬁable elements that
resemble the cells and matrix of cartilage. For such analysis,
the three-grade histopathologic classiﬁcation of Evans is
based on cell type/diﬀerentiation, matrix formation and
architecture, and is at present considered useful for the
prediction of clinical behaviour [11–13]. To date, many
questions still remain unanswered and there is an urgent
need for markers of biologic phenotypic features, that could
be determined in a noninvasive manner, and could be
used as objective criteria of grading, followup, response to
therapy and detection of recurrence. CT and MRI deﬁne
morphology, but are limited in distinguished postoperative
residual and postchemotherapeutic lesions due to altered
tissue planes, edema and ﬁbrosis. Contrast-enhanced MRI,
while providing data for local staging and extraosseous
involvment, appears also limiting in determining biologic
behaviour of lesions [14–16]. SPECT by the use of highly2 Sarcoma
speciﬁc radiolabelled probes, allows a noninvasive and
quantitative assessment of many biochemical pathways in
vivo[17]. In such context, scintigraphic imaging with 99mTc-
NTP 15-5 would be a powerful tool for a direct in vivo
quantitative evaluation of chondrosarcoma at the PG level,
allowing therefore the detection of changes in relation to
pathological processes and/or response to therapies. We
therefore initiated preclinical studies aiming at determining
whether 99mTc-NTP 15-5 imaging could be useful for the
evaluation of the tumoural pathology of cartilage in vivo.
In the present study, the 99mTc-NTP 15-5 imaging was
characterized in the Swarm rat chondrosarcoma implanted
in paratibial location.
2.MaterialsandMethods
2.1. Animals. Male Sprague Dawley (Charles River, France)
were included in this study. They were handled and cared
for in accordance with the guidelines for the Care and Use
of Laboratory Animals (National Research Council, 1996)
and European Directive 86/809/EEC. They were maintained
at 21◦C with a 12h/12h light/dark cycle. Protocols were
performed under the authorisation of the French Direction
of Veterinary Services (Authorisation N◦ C63-113-10) and
conducted by authorized investigators in accordance with
the institution’s recommendations for the use of laboratory
animals.
2.2. Chondrosarcoma Model. The Swarm rat chondrosar-
coma (SRC) line was a generous gift from Dr. P. A. Guerne
(Geneva, Switzerland) as tissue fragments that were frozen
until use.
For tumoural implant, the rats were anaesthetized by
inhalation of a combination isoﬂurane (Abbott, France)/air
(1.5%, 1L/min) associated with an intramuscular injection
of 100mg/kg ketamine (Imalgene, Rhone Merieux, France).
Allograft transplantation of a tumour fragment (10
animals) was performed on the right paw, the other paw
being used as the controlateral reference, as previously
published [18].
Using a lateral approach, the cortical surface of the dia-
physis was scariﬁed laterally on 10mm, a 10mm3 fragment
of SRC was placed contiguous to the scariﬁed surface, and
the muscular and cutaneous wounds were sutured. The same
procedure was performed for the controlateral paw, but no
tumour fragment was implanted. Tumours appeared at the
graft site 7–11 days later.
2.3. Establishment of the Sham Model. Five animals under-
went sham surgery, in which the right paw was submitted to
the same surgery procedure as SRC animals, but no tumour
fragment was implanted.
2.4. Acquisitions for 99mTc-NTP 15-5 Imaging. Scintigraphic
in vivo imaging was performed using a small-animal γ cam-
era(CsI(Na)crystal)equippedwitha1.3/0.2/35parallel-hole
collimator (hole diameter/septum thickness/height in mm)
(Gammaimager, Biospace, France). The energy resolution
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Figure 1: Chemical structure of 99mTc-N-[triethylammonium]-3-
propyl-[15]ane-N5 (99mTc-NTP 15-5).
andintrinsicplanarresolutionofthesystemaregivenas11%
at140keVand<2mmfullwidthathalfmaximum(FWHM),
respectively.
The radiotracer 99mTc-NTP 15-5 (Figure 1) radiotracer
was prepared and radiolabelled as previously published
[1–6], and administered by IV route to vigil animals
(25Mbq/animal) using dedicated contention box.
First of all, a 10-min planar acquisition (with a 15%
window centered on the 140keV photopeak of 99mTc) was
performed on 3 animals with a well-established tumour
(volume = 949.35 ± 223mm3) at several intervals (30,
60, 90 and 120mins) to determine kinetics of tracer accu-
mulation within chondrosarcoma, respectively, to articular
cartilage and muscle. For acquisition, each posterior paw of
animals was positioned over the collimator of the camera
as illustrated in Figure 2. Quantitative analysis of scinti-
graphic scans was performed using the GAMMAVISION+
software (Biospace, France). Regions of interest (ROIs)
were delineated over tumour, femorotibial cartilage and
muscle patterns. For each animal and each ROI, average
count in cpm per pixel was obtained. Two semiquantitative
parameters were determined:
T
M
=
average count in tumour
average count in muscle
,
T
C
=
average count in tumour
average count in femorotibial cartilage
.
(1)
Data were expressed as mean ± standard deviation.
A serial imaging was then performed on primary
chondrosarcoma-bearing rats (n = 10) and sham-operated
animals (n = 5) at regular intervals after surgery (from
day 4 to day 35), with 10-min planar acquisition being
started 30mins after iv administration of 99mTc-NTP 15-
5. Scintigrams were considered positive when tracer uptake
areas corresponded to sites of implant. All the positive
scans were evaluated using the ROI method as described
above, with T/C and T/ M parameters being determined
for each animal at each time point, and data expressed as
mean ± standard deviation. Semi-quantitative parameters
determined at day 4 were used as the “threshold reference
value” and were compared to the mean values determined at
each time point of study (paired 2-sided Student t-test with
a level of signiﬁcance set at P<. 05).Sarcoma 3
Figure 2: In vivo scintigraphic acquisition of chondrosarcoma bearing rats using a small animal dedicated gamma camera.
2.5. Acquisitions for 99mTc-HMDP Bone Imaging. Primary
chondrosarcoma-bearing rats were also submitted to bone
scintigraphies at day 12, day 38, and day 48 after implant.
For each paw, “delayed images” (10-minute duration) were
acquired 2 hours post injection of 99mTc-HMDP radiotracer
(Osteocys, IBA, France; 30MBq/animal).
Bone scintigrams were considered positive when tracer
uptake areas corresponded to sites of implant.
2.6. Tumour Growth Assessment. The tumour volume was
determined from the measurement of 2 perpendicular diam-
eters using a calliper. Tumour volumes (V) were calculated
according to the following formula:
V

mm3
= 0.5 ×L ×(S)
2,( 2 )
where L and S are, respectively, the largest and smallest
perpendicular tumour diameters in mm [19].
2.7. Histology of SRC Tissue. At the end of the study, three
chondrosarcoma-bearing rats were killed for histological
characterization of the tumours. The femora and tumour
of each rat were removed and ﬁxed at 4◦C for 48 hours in
formol buﬀer (pH 7.4). The femora where cut longitudinally
or transversally. Decalciﬁed femoral fragments were embed-
ded in paraﬃna n d5 μm sections were mounted on glass
slides for staining with Hematoxylin-Eosin-Safran (HES)
and Alcian blue.
2.8. PG Content of SRC Tissue. At the end of the study,
SRC were removed (n = 3 animals), dissected and digested
for 24h at 60◦C with EDTA-phosphate buﬀer solution
containing Papaine 0.60mg/mL (Sigma-Aldrich, France)
and DL-dithiothreitol (DTT) 0.25mg/mL (Sigma-Aldrich,
France). Digests were then assessed for PG content using the
dimethylene blue protocol [20].
PG content of SRC tissue was compared to PG content
of mouse B16F0 melanoma as negative control: B16F0
melanoma were removed from bearing mice (n = 3) (stage
day 15 after subcutaneous inoculation of 300000 B16F0
cells),andsubmittedtothesameprocedureofextractionand
digestion as SRC tumours.
3. Results
3.1. SRC Characterisation: Tumoural Growth, Histology and
PG Assay. Tumour volumes were followed for 35 days
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Figure 3: Tumour volume growth for Swarm rat chondrosarcoma
(SRC) implanted in paratibial location. Mean values + standard
deviation are presented at each time point.
after primary implant (Figure 3). All the animals developed
a tumour that became palpable from day 10. Histolog-
ical examination (Figure 4(a))a ts t u d ye n de v i d e n c e da
chondroid tumoural tissue, poorly vascularized, lobular in
organization with lobules containing chondroid stroma and
delimited by ﬁne ﬁbrous septa. Hypercellularity was also
observed. At this later stage of pathology, an extensive
invasionofboneandsurroundingtissueswaspresent,aswell
as osteolysis.
The overall presence of PG was ﬁrst investigated by
Alcian blue staining: as shown in Figure 4(b), a high density
of stained areas were observed in SRC tissue, revealing the
presence of PG in this tumour.
PG content of SRC tumour tissue was also assessed by
biochemical dosage. PG content of SRC tissue was compared
with PG of murine B16F0 melanoma tumour as negative
control: As shown in Figure 5, a high PG content was
observed in SRC tissue (7.46 ± 2.41μg of PG/mg of tissue),
respectively, to melanoma (0.45 ± 0.16μg of PG/mg of
tissue).
3.2. 99mTc-NTP 15-5 Distribution in SRC Tissue, Respectively,
to Muscle and Cartilage. 99mTc-NTP 15-5 distribution in
well-established primary chondrosarcomas was character-
ized at 30, 60, 90 and 120mins after 99mTc-NTP 15-5
administration, on the basis of tumour/muscle (T/M) and
tumour/cartilage (T/C) ratios. As shown in Figure 6(a),
99mTc-NTP 15-5 rapidly accumulated within SRC tissue,4 Sarcoma
(a) (b)
Figure 4: Histomorphological features of the SRC model at study end showing: (a) a tumoural tissue with hypercellularity, and bone
osteolysis (x10); (b) a high density of blue Alcian stained areas as a reﬂect of proteoglycan content (x5).
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Figure 5: PG content of SRC tissue, respectively, to murine
melanoma tumour (as negative control); Mean values + standard
deviation are presented.
with T/M and T/C ratios being 1.44 ± 0.27 and 0.78 ±
0.03 from 30mins post injection. Radiotracer accumulation
within tumoural tissue was observed to be as high as in
cartilage tissue from 60mins pi, with T/C value of 0.90 ±
0.23. No signiﬁcant changes were observed in T/M and T/C
ratios from 60 to 120mins pi.
This high and selective accumulation of 99mTc-NTP 15-
5 within tumour was at the origin of the highly contrasted
chondrosarcoma imaging in vivo, as shown in (Figure 6(b))
for a representative animal.
3.3. Diagnosis Capability of 99mTc-NTP 15-5 Imaging,
Respectively, to 99mTc-HMDP Bone Scintigraphy and Calliper
Measurement. All the implanted animals were positive for
chondrosarcoma at necropsy.
Figure 7 shows the disease incidence according to 99mTc-
HMDP scintigraphy, 99mTc-NTP 15-5 imaging, and calliper
measurement during the whole study of monitoring.
A palpable and measurable tumour was observed from
day 10 after implant for 50% of the animals. From day 20,
100% of the animals evidenced measurable tumours.
99mTc-NTP 15-5 scintigraphy was positive for 66.66% of
the animals as early as day 4 post implant, and for 100% of
the animals from day 10.
99mTc-HMDP bone scintigraphy was negative for SRC
imaging during the whole duration of study, and even later
(48 days post implant).
3.4. Monitoring of SRC Growth In Vivo Using 99mTc-NTP15-5
Imaging. As shown in Figure 8 for a representative animal,
99mTc-NTP 15-5 radiotracer was observed to accumulate
within tumoural tissue, respectively, to the contralateral paw
(Figure 8(a)), as early as day 4 after implant: scintigram
of the tumour bearing paw (Figure 8(b))e v i d e n c e d( i )
uptake areas in femorotibial articular cartilage, with the
tibial plateau uptake clearly distinguished from the femoral
condyle uptake, (ii) accumulation at the site of implant.
99mTc-NTP15-5examinationofthesameanimalatlatestage
of pathology (day 35, Figure 8(c)) evidenced that radiotracer
accumulation within the tumour-bearing paw was highly
increased, respectively, to day 4.
99mTc-NTP 15-5 accumulation was quantitatively
assessed in vivo in the tumour, respectively, to muscle and
cartilage (as T/M and T/C uptake ratios, resp.) as a function
of time after implant (Figure 9): As early as day 4 post
implant, the mean T/M and T/C values were 1.61 ± 0.14 and
0.57 ± 0.06, respectively. From day 10, tumoural uptake of
99mTc-NTP 15-5 was as high as cartilage uptake with T/C =
1.08 ± 0.09; T/M value was 2.55 ± 1.15.
Atstudyending(day35),meanT/CandT/Mvalueswere
1.61 ± 0.06 and 3.97 ± 0.74, respectively.
3.5. Monitoring of Sham-Operated Animals Using 99mTc-NTP
15-5 Imaging. Serial 99mTc-NTP 15-5 imaging of sham-
operated animals (n = 5) performed over 50 days afterSarcoma 5
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Figure 6: 99mTc-NTP 15-5 in vivo distribution in chondrosarcoma;
(a) 99mTc-NTP 15-5 uptake ratios as a function of delay between
iv administration of tracer and acquisition; (b) Scintigraphic image
obtained for a representative animal, for a delay of 30min between
injection and acquisition. Abbreviations: F: femoral condyle; T:
tibial plateau; CHS: chondrosarcoma.
surgery did not evidence any accumulation of the tracer at
site of surgery.
4. Discussion
This experimental study was conducted in the syngeneic
model of SRC that has been the subject of extensive
biochemical studies on extracellular matrix and chondrocyte
metabolism [21, 22]. Histological characterization of SRC
implanted in paratibial location, evidenced a chondroid
tumoural tissue, poorly vascularized, lobular in organization
with lobules containing chondroid stroma delimited by ﬁne
ﬁbrous septa. In the present study PG were conﬁrmed (by
both alcian blue staining and biochemical assay) as being a
major component of SRC tissue. The high concentration of
PG in the tumour is at the origin of a high density of ECM
strong negative charges that may interact with the positively
charged quaternary ammonium moiety of the 99mTc-NTP
15-5 radiotracer. The ability of 99mTc-NTP 15-5 to image
SRC tissue was therefore demonstrated from 30mins post
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Figure7:Diseaseincidenceateachtimepointofstudy,accordingto
99mTc-HMDP scintigraphy, 99mTc-NTP 15-5 imaging, and calliper
measurement.
injectionwithT/MandT/Cratiosbeing1.44 ±0.27and0.78
± 0.03.
Interestingly, tracer accumulation was detected at early
stage (day 4) and for about 70% of the animals investigated,
whereas no palpable nor measurable tumour was evidenced.
Such early accumulation raised the question of whether the
imaging pattern represented an eﬀective tumoural uptake or
a surgery-induced inﬂammation. Negative 99mTc-NTP 15-5
imagingobservedforsham-operatedanimalsdeﬁnitelyruled
out the hypothesis of inﬂammation contribution.
99mTc-NTP 15-5 accumulation within SRC was assessed
at multiple time-points of tumoural growth using a semi-
quantitative method. As tumour developed over time, mean
T/MandT/Cvalueswereobservedtobeincreasedbyafactor
of 2.4 and 2.8, respectively, between the early stage day 4
and the late stage day 35. Tumour to femorotibial cartilage
uptake ratio (T/C parameter) is of particular importance
for clinical application (in patients, tumour is located in the
joint). From our results, the increase in T/C with pathology
argued in favour of a high tumour/cartilage contrast which
would expect diagnosis of tumour occurrence within the
joint.
Another interesting result of this study is that 99mTc-
HMDPbonescintigraphycommonlyusedinclinicalpractise
failed to image tumoural tissue throughout the study,
whereas 99mTc-NTP 15-5 imaging was positive.
These preclinical results underlined the suitability and
high sensitivity of 99mTc-NTP 15-5 scintigraphic imaging for
assessing in vivo the PG component of chondrosarcomas,
providing therefore criteria for a quantitative and functional
assessment of the tumoural pathology in vivo.
Our results raised the question of whether 99mTc-NTP
15-5 imaging patterns in benign cartilage tumours, (which
are known to form a cartilaginous PG—rich matrix), would
be the same as for malignant tumours. According to many
histological studies, the neoplastic cells of benign cartilage
tumourssuchaschondroblastomadidnotshow,atanypoint
oftheirevolution,realcartilagematrixformation[13,23].As6 Sarcoma
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Figure 8: 99mTc-NTP 15-5 longitudinal in vivo examination of a representative SRC-bearing rat; (a) in vivo scintigraphic image of the
contralateral paw at day 4; (b) in vivo scintigraphic image of the tumour-bearing paw at day 4; (c) in vivo scintigraphic image of the tumour
bearing paw of the same animal at day 35. A clear accumulation of radioactivity within tumoural tissue was observed as early as day 4 after
implant (Image b, arrow); abbreviations: CHS = chondrosarcoma.
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ac onsequenc e,adiﬀerentialaccumulationof 99mTc-NTP15-
5 radiotracer could be expected. Since the biological nature
of benign cartilage tumours is still debating, we will have
to elucidate this aspect by performing a preclinical 99mTc-
NTP 15-5 imaging study of rodent models of enchondroma,
(such as mutant mice for hedgehog signalling pathways
or Ext1/Ext2 exostosin encoding gene) in parallel to the
biological characterization of PG of tissue [23–25].
From a clinical point of view, the distinction between
benign and low-grade malignant pathology, is known to be
extremely diﬃcult both at radiologically and histologically,
and remains a challenge [9, 26]. All current imaging
modalities have shown their limitations. Radiographs, CT,
MRI and contrast enhanced MRI provide morphological
data for local staging and extra-osseous involvement, but
appeared limited in determining functional markers of
postoperative recurrence, response or relapse to therapies
[9, 27–29]. In such context, 99mTc-NTP 15-5 radiotracer
may serve as an adjunct to CT and MRI, by supplying
quantitative data which would allow imaging and follow-
up to be functionally rather than morphologically based.
For functional imaging of cartilage neoplasms, radiotracers
currentlyavailableprovideindirectevaluationsofthepathol-
ogy, such as bone remodeling and inﬂammation features,
but do not allow biological assessment of the tumour. Many
tumour seeking agents such as 201Tl, 99mTc-MIBI, 99mTc-
Tetrofosmin, 99mTc-DMSA(V) and more recently 18F-FDG
have been found useful in an initial diagnosis and grading,
buttheyhavealsodemonstratedtheirlimitationsforimaging
chondrosarcoma with low cellularity and low vascularity
[30–33]. 99mTc-NTP 15-5 imaging would allow a regular in
vivo follow up, in order to evidence any “upregulation” or
“downregulation” synthesis of PG, as the reﬂect of potential
malignant transformation, recurrence, response or relapse to
therapies. We strongly believe in such potential application
since 99mTc-NTP15-5imagingrecentlyevidencedintheSRC
model a “downregulation synthesis” of PG as a result of
anticancer treatment (unpublished data).
Another potential application of 99mTc-NTP 15-5 imag-
ing in chondrosarcoma would be the early imaging of metas-
tasis. As a consequence, the sensitivity of 99mTc-NTP 15-5
imagingfortheearlyevaluationofchondrosarcomametasta-
sishastobedeterminedinrelevantpreclinicalanimalmodels
of chondrosarcoma with spontaneous metastasis [34, 35].
5. Conclusion
This preliminary work in the orthotopic SRC model under-
lined the suitability and high sensitivity of 99mTc-NTP
15-5 radiotracer for imaging chondrosarcoma at the PG
level. 99mTc-NTP 15-5 imaging provided a suitable set
of quantitative criteria for the in vivo characterization ofSarcoma 7
chondrosarcoma behaviour in bone environment, which
could be useful for achieving a greater understanding of the
pathology.
Inviewofapotentialclinicalapplication, 99mTc-NTP15-
5 imaging appears of interest for (i) the establishment of the
cartilaginous nature of “musculoskeletal” tumours (ii) the in
vivo assessment to PG changes associated to the evolution
of pathological process, local recurrence, response or relapse
to therapies. Additional preclinical studies are needed to
investigate the potential of 99mTc-NTP 15-5 imaging in the
tumoral pathology of cartilage.
Acknowledgments
The authors received grants from Institut National du
Cancer, “projet libre intercanc´ eropˆ ole CLARA/Grand
Ouest”, Ligue Contre le Cancer, Regional Innovation Fund
FRI2/OSEO, Auvergne Region for “Contrat de Projets Etat
Region”.
References
[1] J. C. Madelmont, I. Giraud, C. Nicolas et al., “inven-
tors. Cyclopharma Laboratoires, assignee. Novel quaternary
ammonium derivatives, method for preparing same and
pharmaceutical use,” International patent PCT WO 01/00621
A1. January 2001.
[2] C. Nicolas, M. Borel, J. C. Maurizis et al., “Synthesis of N-
quaternary ammonium [3H] and [99mTc]Polyazamacrocycles,
potential radiotracers for cartilage imaging,” Journal of
Labelled Compounds and Radiopharmaceuticals,v o l .4 3 ,n o .6 ,
pp. 585–594, 2000.
[ 3 ]J .C .M a u r i z i s ,M .R a p p ,C .N i c o l a s ,M .O l l i e r ,M .V e r n y ,
and J. C. Madelmont, “Disposition in rats of N-pyridinium-
propyl-cyclam, N- triethylammoniumpropyl-cyclam, and N-
[triethylammonium]-3-propyl-[15]ane-N5, potential carti-
lage imaging agents,” Drug Metabolism and Disposition, vol.
28, no. 4, pp. 418–422, 2000.
[4] M. Ollier, J. C. Maurizis, C. Nicolas et al., “Joint scintigraphy
in rabbits with 99mTc-N-[3-(triethylammonio)propyl]-15ane-
N5, a new radiodiagnostic agent for articular cartilage imag-
ing,” Journal of Nuclear Medicine, vol. 42, no. 1, pp. 141–145,
2001.
[5] E. Miot-Noirault, A. Vidal, P. Pastoureau et al., “Early detec-
tionandmonitoringofcartilagealterationintheexperimental
meniscectomised guinea pig model of osteoarthritis by 99mTc-
NTP 15-5 scintigraphy,” European Journal of Nuclear Medicine
and Molecular Imaging, vol. 34, no. 8, pp. 1280–1290, 2007.
[6] E. Miot-Noirault, A. Vidal, P. Auzeloux, J. C. Madelmont,
J. Maublant, and N. Moins, “First in vivo SPECT imaging
of mouse femorotibial cartilage using 99mTc-NTP 15-5,”
Molecular Imaging, vol. 7, no. 6, pp. 263–271, 2008.
[7] F. Lamoureux, M. Baud’huin, L. Duplomb, D. Heymann, and
F. R´ edini, “Proteoglycans: key partners in bone cell biology,”
BioEssays, vol. 29, no. 8, pp. 758–771, 2007.
[8] World Health Organization, “Cartilage tumours,” in World
Health Organization Classiﬁcation of Tumours: Pathology and
Genetics, Tumours of Soft Tissue and Bone,C .D .M .F l e t c h e r ,
K. K. Unni, and F. Mertens, Eds., pp. 234–257, IARC Press,
Lyon, France, 2002.
[ 9 ]H .G e l d e r b l o m ,P .C .W .H o g e n d o o r n ,S .D .D i j k s t r ae ta l . ,
“The clinical approach towards chondrosarcoma,” Oncologist,
vol. 13, no. 3, pp. 320–329, 2008.
[10] W. A. Chow, “Update on chondrosarcomas,” Current Opinion
in Oncology, vol. 19, no. 4, pp. 371–376, 2007.
[11] H. L. Evans, A. G. Ayala, and M. M. Romsdahl, “Prognostic
factors in chondrosarcoma of bone. A clinicopathologic
analysis with emphasis on histologic grading,” Cancer, vol. 40,
no. 2, pp. 818–831, 1977.
[12] F. Schajowicz, L. H. Sobin, and World Health Organization,
International Histological Classiﬁcation of Tumours, Histologi-
cal Typing of Bone Tumours, Springer, Berlin, Germany, 1993.
[13] T. Aigner, “Towards a new understanding and classiﬁcation of
chondrogenic neoplasias of the skeleton—biochemistry and
cell biology of chondrosarcoma and its variants,” Virchows
Archiv, vol. 441, no. 3, pp. 219–230, 2002.
[ 1 4 ]L .O l l i v i e r ,D .V a n e l ,a n dJ .L e c l ` ere, “Imaging of chondrosar-
comas,” Cancer Imaging, vol. 4, pp. 36–38, 2003.
[15] F. Feldman, R. van Heertum, and C. Manos, “18FDG PET
scanning of benign and malignant musculoskeletal lesions,”
Skeletal Radiology, vol. 32, no. 4, pp. 201–208, 2003.
[16] S. E. Anderson, L. S. Steinbach, S. Schlicht, G. Powell, M.
Davies, and P. Choong, “Magnetic resonance imaging of bone
tumors and joints,” Topics in Magnetic Resonance Imaging, vol.
18, no. 6, pp. 457–465, 2007.
[17] R. J. Hicks, G. C. Toner, and P. F. Choong, “Clinical
applications of molecular imaging in sarcoma evaluation,”
Cancer Imaging, vol. 5, no. 1, pp. 66–72, 2005.
[18] E. Grimaud, C. Damiens, A. V. Rousselle, N. Passuti, D.
Heymann, and F. Gouin, “Bone remodelling and tumour
grade modiﬁcations induced by interactions between bone
and Swarm rat chondrosarcoma,” Histology and Histopathol-
ogy, vol. 17, no. 4, pp. 1103–1111, 2002.
[19] F. Gouin, B. Ory, F. R´ edini, and D. Heymann, “Zoledronic
acid slows down rat primary chondrosarcoma development,
recurrent tumor progression after intralesional curretage and
increases overall survival,” International Journal of Cancer, vol.
119, no. 5, pp. 980–984, 2006.
[20] R.W.Farndale,D.J.Buttle,andA.J.Barrett,“Improvedquan-
titation and discrimination of sulphate glycosaminoglycans by
useofdimethylmethylene blue,” BiochimicaetBiophysicaActa,
vol. 883, no. 2, pp. 173–177, 1986.
[21] G. K. Hascall, “Ultrastructure of the chondrocytes and extra-
cellularmatrixoftheSwarmratchondrosarcoma,”Anatomical
Record, vol. 198, no. 2, pp. 135–146, 1980.
[22] D. Breitkreutz, L. Diaz de Leon, and L. Paglia, “Histological
and biochemical studies of a transplantable rat chondrosar-
coma,” Cancer Research, vol. 39, no. 12, pp. 5093–5100, 1979.
[23] T. Aigner, S. Loos, C. Inwards et al., “Chondroblastoma is
an osteoid-forming, but not cartilage-forming neoplasm,”
Journal of Pathology, vol. 189, no. 4, pp. 463–469, 1999.
[24] S. Hopyan, P. Nadesan, C. Yu, J. Wunder, and B. A. Alman,
“Dysregulation of hedgehog sinalling predisposes to synovial
chondromatosis,”JournalofPathology,vol.206,no.2,pp.143–
150, 2005.
[25] J. V. M. G. Bov´ ee, “EXTra hit for mouse osteochondroma,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 107, no. 5, pp. 1813–1814, 2010.
[26] X. L. Wang, L. H. De Beuckeleer, A. M. A. De Schepper, and
E. Van Marck, “Low-grade chondrosarcoma vs enchondroma:
challenges in diagnosis and management,” European Radiol-
ogy, vol. 11, no. 6, pp. 1054–1057, 2001.
[27] J. V. M. G. Bovee and P. C. W. Hogendoorn, “Cartilage-
forming tumours of bone and soft tissue and their diﬀerential
diagnosis,”CurrentDiagnosticPathology,vol.7,no.4,pp.223–
234, 2001.8 Sarcoma
[28] J. V. M. G. Bov´ ee, A. M. Cleton-Jansen, A. H. M. Taminiau,
and P. C. W. Hogendoorn, “Emerging pathways in the
development of chondrosarcoma of bone and implications for
targeted treatment,” Lancet Oncology, vol. 6, no. 8, pp. 599–
607, 2005.
[29] J. V. M. G. Bov´ ee, “Multiple osteochondromas,” Orphanet
Journal of Rare Diseases, vol. 3, no. 1, pp. 1–7, 2008.
[30] S. G. Pneumaticos, S. N. Chatziioannou, W. H. Moore,
and M. Johnson, “The role of radionuclides in primary
musculoskeletal tumors beyond the ’bone scan’,” Critical
Reviews in Oncology/Hematology, vol. 37, no. 3, pp. 217–226,
2001.
[31] G. B¨ uy¨ ukdereli, ¨ O. Sargin, and S. ¨ Ozbarlas, “Tc-99m tetrofos-
min imaging in chondrosarcoma,” Clinical Nuclear Medicine,
vol. 25, no. 1, pp. 64–65, 2000.
[32] P. F. M. Choong, T. Kunisada, J. Slavin, S. Schlicht, and R.
Hicks, “The role of thallium-201 and pentavalent dimercapto-
succinic acid for staging cartilaginous tumours,” International
Seminars in Surgical Oncology, vol. 8, pp. 1–7, 2004.
[ 3 3 ]F .Y .I .L e e ,J .Y u ,S .S .C h a n g ,R .F a w w a z ,a n dM .V .
Parisien, “Diagnostic value and limitations of ﬂuorine-18
ﬂuorodeoxyglucose positron emission tomography for carti-
laginous tumors of bone,” Journal of Bone and Joint Surgery A,
vol. 86, no. 12, pp. 2677–2685, 2004.
[34] J. C. M. Clark, C. R. Dass, and P. F. M. Choong, “Development
of chondrosarcoma animal models for assessment of adjuvant
therapy,” ANZ Journal of Surgery, vol. 79, no. 5, pp. 327–336,
2009.
[35] J. C. M. Clark, T. Akiyama, C. R. Dass, and P. F. M. Choong,
“New clinically relevant, orthotopic mouse models of human
chondrosarcoma with spontaneous metastasis,” Cancer Cell
International, vol. 20, pp. 1–10, 2010.